Abstract: An ELISpot diagnosis kit for NMO and its application are characterized in that, the polypeptide fragment specific to NMO effector T-cell is obtained through topological conformation analysis of aquaporin-4 (AQP-4), followed by the structural analyses of the related polypeptides after combination and rearrangement so as to screen out the brand-new polypeptide fragment suitable for NMO disease diagnosis. In the ELISpot experiment, by utilizing the obtained polypeptide fragment, stimulate the effector T-cell in the NMO disease to secrete IL-4, proving the feasibility and scientific value of that polypeptide fragment in the NMO diagnosis. This method is with strong specificity, high sensitivity and easy operations, and it can be developed into the diagnosis kit for the diagnosis and differential diagnosis of NMO in the clinical examination, laying the foundation for the early discovery and treatment of NMO.

Abstract: Intermolecular disulfide stabilized foldon polypeptides are provided.

Abstract: An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and/or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.

Abstract: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions containing the same, methods for producing the same, and methods for using the same are also disclosed, wherein the peptide constructs have the formula P1-x-P2, where P2 is a peptide associated with an infectious agent and P1 is a peptide that will bind to a class of immune cells, such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cell can be administered to a subject to modulate or initiate an immune response against an infectious agent.

Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.

Abstract: A synthetic peptide modeled on the IRCX binding area of NHE3, is a competitive inhibitor of the IRCX and both stimulates basal NHE3 activity and prevents elevated Ca2+ and cAMP inhibition of NHE3. Methods of its preparation and use in the prevention and/or treatment of gastrointestinal disease, such as diarrhea are provided.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.

Abstract: The invention relates to biomimetic peptide-containing compositions for use, in particular, for application and or deposition on a magnesium alloy, e.g., substrate, to at least partially coat a surface of the magnesium alloy. The invention also relates to the coated magnesium alloy which is particularly useful for tissue and bone repair and regeneration applications, such as, for constructing medical implant devices.

Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.

Abstract: Disclosed are novel peptides that are useful, for example, for detecting target proteins having a ?-sheet secondary structure which may be associated with a disease, and for diagnosing and treating such a disease. Related methods and kits also are disclosed.

Abstract: Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described.

Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.

Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.

Abstract: Nutritive proteins comprising no phenylalanine (Phe) are provided. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present a benchmark protein.

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.

Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.

Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.

Abstract: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.

Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.

Abstract: The present invention generally relates to processes and methods of peptide and protein synthesis. The present invention also relates to specific compounds for use in such processes and methods. It is shown herein that peptides with a C-terminal tertiary N,N-bis(2-mercaptoethyl)-amide (BMEA) undergo N-to-S acyl transfer at weakly acidic pH to form a transient thioester which can be captured for direct ligation with a cysteinyl peptide. These C-terminal BMEA peptides are easily prepared with standard Fmoc solid-phase synthesis protocols, thus giving a very convenient access to the thioester components for native chemical ligation.

Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.

Abstract: A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.

Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.

Abstract: The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine.

Abstract: A radio- or chemo-sensitizing compound is described herein. The compound comprises a nanoparticle and attached to the nanoparticle; (i) a DNA repair inhibitor; and (ii) a nuclear localization signal element (NLS); each optionally attached via one or more linker moieties.

Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.

Abstract: N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2?,3?-dideoxycytidine. Preventing CRMP-2—mediated enhancement of CaV2.

Abstract: Improved synthetic copolypeptide antimicrobials contain cationic amino acid residues and may be based on a blocky sequence. These antimicrobials show low mammalian toxicity and may undergo directed self-assembly. The inventive synthetic copolypeptides are useful in treatment of wounds and other infections.

Abstract: The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well as methods of using the same.

Abstract: Peptide analogues of PYY, compositions comprising said analogues and methods of using said analogues for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for a reduction in appetite, reduction in food intake or reduction of calorie intake in a subject.

Abstract: The invention provides modified collagen and related therapeutic and diagnostic methods.

Abstract: There is provided peptides for inhibiting growth of cancer cells, the peptides comprising the amino acid sequence RxKxKxxxxR wherein K and R are respectively lysine and arginine amino acid residues, each x is independently an amino acid, and 5 wherein the peptide has 50% or less amino acid sequence identity with the amino acid sequence RSKAKNPLYR (SEQ ID. No. 2). Each x amino acid may independently be an amino acid residue selected from the group consisting of alanine (A), valine (V), leucine (L), isoleucine (I), threonine (T) and serine (S) amino acid residues. There is also provided chimeric proteins incorporating a peptide of the amino acid sequence 10 RxKxKxxxxR, nucleic acids encoding for the peptide, expression vectors including a nucleic acid encoding the peptide for expression of the peptide, and methods for use of the peptide for inhibiting growth of cancer cells.

Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.

Abstract: Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.

Abstract: The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.

Abstract: Neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders are described.

Abstract: Crystalline formulations of therapeutic peptides, along with methods for making and using the same, are provided.

Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.

Abstract: Isolated polynucleotides encoding Macaca fascicularis CCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.

Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.

Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.

Abstract: Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such peptides while providing all potential T cell epitopes are devoid of the three-dimensional structure of the original allergen, therefore reducing their ability to bind IgE.

Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate MEK activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.

Abstract: The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.